Skip to content

Development of enantioselective high-performance liquid chromatography-tandem mass spectrometry method for the quantitative determination of 3,4-methylenedioxy-methamphetamine (MDMA) and its phase-1 metabolites in human biological fluids.

Alfredo Fabrizio Lo Faro, Giorgia Sprega, Diletta Beradinelli, Anstasio Tini, Lourdes Poyatos, Esther Papaseit, Paolo Berretta, Alessandro Di Giorgi, Magí Farré, Nino Takaishvili, Tivadar Farkas, Francesco Paolo Busardò, Bezhan Chankvetadze

Journal of Pharmaceutical and Biomedical Analysis January 20, 2024 DOI: 10.1016/j.jpba.2023.115768 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Method development and validation Peer reviewed
Population Human plasma, sweat, oral fluid, and urine
Topics MDMA
Keywords Chiral hplc Enantioselective metabolism
Citations 14
Key points Enantioselective LC-MS/MS methods using two chiral columns enabled baseline separation of MDMA and most of its phase-1 metabolites in human biological fluids, confirming enantioselective metabolism of MDMA.

Abstract

In the present study enantioselective high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods were developed for the quantitative determination of 3,4-methylenedioxy-methamphetamine (MDMA) and its major phase-1 metabolites 4-hydroxy-3-methoxyamphetamine (HMA), 4-hydroxy-3-methoxymethamphetamine (HMMA) and 3,4-methylenedioxyamphetamine (MDA) in human plasma, sweat, oral fluid (OF) and urine. The simultaneous separation of all these compounds and their respective enantioseparation was accomplished on two polysaccharide-based chiral columns. The Lux AMP column with a proprietary chiral selector enabled baseline separation of the enantiomers of MDMA, HMA and HMMA while MDA enantiomers could not be separated with this column under the experimental conditions used in this study. The Lux i-Amylose-3 column based on amylose tris(5-chloro-3-methylphenylcarbamate) as chiral selector baseline-separated the enantiomers of MDMA, HMMA and MDA while the enantiomers of HMA could not be separated. Thus, the various samples were analyzed by using both columns alternatively in combinations with acetonitrile containing 25% (v/v) 5 mM ammonium bicarbonate buffer at pH 11.0 as mobile phase. Analysis time was less than 4 min with the Lux AMP column and less than 6 min with the Lux i-Amylose-3 column. Both methods were validated and applied to the enantioselective determination of MDMA and its phase-I metabolites in human biological fluids, and enantioselective metabolism of MDMA was confirmed.